# Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

> **NCT01634061** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** BEZ235
- **DRUG:** BKM120
- **DRUG:** BEZ235
- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01634061
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634061, "Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01634061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*